Biology and genetics of colorectal cancer

European Journal of Cancer

Volumn 37, Issue SUPPL. 7, 2001, Pages

  Walker, Julie ^a   Quirke, Phil ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; COLORECTAL TUMOR; GENE THERAPY; GENETICS; HUMAN; IMMUNOTHERAPY; METHODOLOGY; PATHOLOGY; PEDIGREE; REVIEW;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; GENE THERAPY; HUMANS; IMMUNOTHERAPY; PEDIGREE;

EID: 0000706625     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(01)80018-6     Document Type: Article

References (123)

1. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinomas and normal tissue examined by oligonucleotide arrays. Cancer Res 2001, 61: 24-30.
2. Maughan NJ, Lewis F, Smith V. An introduction to arrays. J Pathol 2001, 193: 1-4.
3. Budendorf L, Nocito A, Moch H et al. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 2001, 195: 72-79.
4. Breivik J, Gaudernack G. Carcinogenesis and natural selection: a new perspective to the genetics and epigenetics of colorectal cancer. Adv Cancer Res 1999, 76: 187-212.
5. Nascimbeni R, Villanacci V, Mariani PP, Di Betta E, Ghirardi M, Donato F, Salerni B. Aberrant crypt foci in the human colon. Am J Surg Pathol 1999, 23: 1256-1263.
6. Schlemper RJ, Borchard F, Dixon MF et al. International comparability of the pathological diagnosis for early cancer of the digestive tract. J Gastroenterol 2000 (35 Suppl): 12, 102-110.
7. Scott RJ, Meldrum C, Crooks R et al. Familial adenomatous polyposis: more evidence for disease diversity and genetic heterogeneity. Gut 2001, 48: 508-514.
8. Heppner Goss K, Groden J. Biology of the adenomatous polyposis coli tumour suppressor. J Clin Oncol 2000, 18: 1967-79.
9. Hinoi T, Yamamoto H, Kishida M et al. A complex formation of adenomatous polyposis coli gene product and axin facilitates glycogen synthase kinase-3 beta-dependent phosphorylation of beta-catenin and down-regulates beta-catenin. J Biol Chem 2000, 275: 34399-34406.
10. Evans DG. Walsh S, Jeacock J et al. Incidence of hereditary non-polyposis colorectal cancer in a population-based study of 1137 consecutive cases of colorectal cancer. Br J Surg 1997,84: 1281-1285.
11. Aaltonen LA, Salovaara R, Kristo P et al. Incidence off hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Eng J Med 1998, 338: 1481-1487.
12. Wijnen J, de Leeuw W, Vasen H et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 1999, 23: 142-144.
13. Kolodner RD, Tytell JD, Semeits JL et al. Germline mutations in colorectal cancer families. Cancer Res 1999, 59: 5068-5074.
14. Miyaki M, Konishi M, Tanaka K et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997, 17: 271-272.
15. Akiyama Y, Sato H, Yamada T et al. Germline-mutation of the hHSH6/GTBP gene in an atypical hereditary nonpolyposis cancer kindred. Cancer Res 1997, 59: 5068-5074.
16. Nicolaides NC, Papadopoulos N, Liu B et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994, 371: 75-80.
17. Jirieny J, Nystrom-Lahti M. Mismatch repair defects in cancer. Curr Opin Genet Dev 2000, 10(2): 157-161.
18. Olschwang S, Hamelin R, Laurent-Puig P et al. Alternative genetic pathways in colorectal carcinogenesis. Proc Natl Acad Sci USA 1997, 94: 12122-12127.
19. Souza RF, Appel R, Yin J et al. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat Genet 1996, 14: 255-257.
20. Rampino N, Yamamoto H, Ionov Y et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997, 275(5302): 967-969.
21. Duval A, Gayet T, Zhou XP et al. Frequent frameshift mutations of the TCF-4 gene in colorectal cancers with microsatellite instability. Cancer Res 1999, 59: 4213-4215.
22. Riccio A, Aaltonen LA, Godwin AK et al. The DNA repair gene MBD4 (MED1) is mutated in human carcinomas with microsatellite instability. Nat Genet 1999, 23: 266-268.
23. Codegoni AM, Bertoni F, Colella G et al. Microsatellite instability and frame shift mutations in genes involved in cell cycle progression or apoptosis in ovarian cancer. Oncol Res 1999, 11: 297-301.
24. Thiodeau SN, French AJ, Cunningham JM et al. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principle involvement of hMLH1. Cancer Res 1998, 58: 1713-1718.
25. Wright CM, Dent CF, Barker M et al. Prognostic significance of extensive microsatellite instability in sporadic cliniopathological stage C colorectal cancer. Br J Surg 2000, 87: 1197-1202.
26. Michael-Robinson JM, Biemer-Huttmann A, Purdig DM et al. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 2001, 48: 360-366.
27. Cawkwell L, Gray S, Murgatroyd H, Sutherland F, Haine L, Longfellow M, O'loughlin S, Cross D, Kronborg O, Fenger C, Mapstone N, Dixon, Quirke P. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 1999, 45: 409-415.
28. Marcus VA, Madensky L, Gryfe R et al. Immunhistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumours. Am J Pathol 1999, 23: 1248-1255.
29. Terdiman JP, Gum JR, Conrad PG et al. Efficient detection of Hereditary Nonpolyposis Colorectal Cancer Gene Carriers by screening for tumor microsatellite instability before germline genetic testing. Gastroenterology 2001, 120: 21-30.
30. Peutz JLA. A very remarkable case of familial polyposis of mucous membrane of intestinal tract and accompanied by peculiar pigmentations of skin and mucous membranes. Ned Maandschr Geneeskunde 1921, 10: 134-146.
31. Jeghers H, Mckusick VA, Katz KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits. N Engl JMed 1949, 241: 1031-1036.
32. Giardielio FM, Welsh SB, Hamilton SR et al. Increased risk of cancer in peutz-jeghers syndrome. N Engl J Med 1987, 316: 1511-1514.
33. Hemminki A, Tomlinson I, Markie D et al. Localization of a susceptibility locus for peutz-jeghers syndrome. Nat Genet 1997, 15: 87-90.
34. Hemminki A, Markie D, Tomlison I et al. A serine/threonine kinase gene defect in peutz-jeghers syndrome. Nature 1998, 391: 184-187.
35. Tiainen M, Yukorkala A, Makela TP. Growth suppression by LKb1 is mediated by a G1 cell cycle arrest. Proc Natl Acad Sci USA 1999, 96: 9248-9251.
36. Mehenni H, Blouin JL, Radhakrishna U et al. Peutz-jeghers: confirmation of linkage to chromosome 19p13.3 and identification of a potential second locus; on 19p13.4. Am J Hum Genet 1997, 61: 1327-1334.
37. Entius MM, Keller JJ, Westerman AM. Molecular genetic alterations in hamartomatous polyps and carcinomas of patients with peutz-jeghers syndrome. J Clin Pathol 2001, 54: 126-131.
38. Howe JR, Mitros FA, Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 1998, 5: 751-756.
39. Howe JR, Ringold JC, Summer RW et al. A gene for familial juvenile polyposis maps to chromosome 18q21.1. Am J Hum Genet 1998, 62: 1129-1136.
40. Woodford-Richens K, Williamson J, Bevan S et al. Allelic loss at SMAD4 in polyps from juvenile polyposis patients and use of fluorescence in situ hybridization to demonstrate clonal origin of the epithelium. Cancer Res 2000, 60(9): 2477-2482.
41. Matsushita M, Matsuzaki K, Date M et al. Down-regulation of TGF-beta receptors in human colorectal cancer: implications for cancer development. Br J Cancer 1999, 80(1-2): 194-205.
42. Laken SJ, Petersen GM, Gruber SB, Oddoux C, Ostret H, Giardielio FM, Hamilton SR, Hampel H, Markowitz A, Klimstra D, Jhanwar S, Winaver S, Offit K, Luce MC, Kinzler KW, Vogelstein B. Familial colorectal cancer in Ashkenazi due to a hypermutable tract in APC. Nat Genet 1997, 17: 70-83.
43. Stern HS, Viertelhausen S, Hunter AGW, O'Rourke K, Cappelli M, Perras H, Serfas K, Blumenthall A, Dewar D, Baumann E, Lagarde AE. APC I1307K increases risk of transition from polyp to colorectal carcinoma in Ashenazi Jews. Gastroenterology 2001, 120: 392-400.
44. Vatn MN, Stalsberg H. The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer 1982, 49: 819-25.
45. Lamlum H, Ilyas M, Rowan A et al. The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's two hit hypothesis. Nat Med 1999, 5(9): 1071-1075.
46. Sheng H, Shao J, Morrow JD et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998, 58: 362-366.
47. He TC, Chan TA, Vogelstein B et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999, 99: 333-345.
48. Yamamoto Y, Yin MJ, Lin KM et al. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 1999, 274: 27307-14.
49. Tsujii M, Kawano S, Tsjui S et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93: 705-716.
50. Bos JL. Ras oncogenes in human cancer: a review. Cancer 1989, 49: 4682-4689.
51. Esteller M, Toyota M, Sanchez-Cespedes M et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000, 60: 2368-71.
52. 6methylguanine DNA methyltransferase characterises a subset of colorectal cancer with low level DNA microsatellite instability. Cancer Res 2001, 61: 827-830.
53. 6-akly guanine DNA-alkyltransfearse activity in normal colorectal tissue is associated with colorectal tumours containing GC → AT transition in the K-ras oncogene. Carcinogenesis 1997, 18: 1299-1302.
54. Arends JW. Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol 2000, 190: 412-416.
55. Zhou S, Kinzler KW, Vogelstein B et al. Going MAD with SMADS. N Engl J Med 1999, 341: 1144-1146.
56. Riggens GJ, Thiagalingam S, Rozenbulm E et al. MAD related genes in human cancer. Nat Genet 1996, 13: 347-349.
57. Herbergs J, Arends JW, Bongers EM et al. Clonal origin of trisomy for chromosome 7 in the epithelial component of colon neoplasia. Genes, Chromosomes Cancer 1996, 16: 106-112.
58. Meijer GA, Hermsen MA, Baak JP et al. Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by comparative genomic hybridisation. J Clin Pathol 1998, 51: 901-909.
59. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997, 88: 323-331.
60. Prives C, Hall PA. The p53 pathway. J Pathol 1999, 187: 112-126.
61. Fodde R, Kuipers J, Rosenberg C et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 2001, 3: 433-438.
62. Quirke P, Durdey P, Dixon MF et al. The prognostic significance of DNA aneuploidy and cell proliferation in rectal adenocarcinomas. J Pathol 151, 285-292.
63. van den Inghe HF, Griffioen G, Cornelisse CJ. DNA aneuploidy in colorectal adenomas. Br J Cancer 1987, 55: 351.
64. Goh HS, Jass JR. DNA content and the adenoma-carcinoma sequence in the colorectum. J Clin Pathol 1986, 39: 387-392.
65. Cahill DP, Lengauer C, Yu J et al. Mutations of mitotic checkpoints genes in human cancer. Nature 1998, 392(6673): 300-303.
66. Nasmyth K, Peters J-M, Uhlmann. Splitting the chromo-some: cutting the ths that bind sister chromatids. Science 2000, 288: 1379-84.
67. Jallepalli PV, Waizenegger IC, Bunz F et al. Securin is required for chromosomal stability in human cells. Cell 2001, 105: 445-447.
68. Ried T, Knutzen R, Steinbeck R et al. Comparative genomic hybridation reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumours. Genes, Chromosomes Cancer 1996, 15: 234-245.
69. Muleris M, Salmon Rj, Dutrillaux B et al. Cytogenetics of colorectal adenocarcinomas. Cancer Genet Cytogenet 1990, 46: 143-156.
70. Brabletz T, Jung A, Dag S et al. Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999, 155: 1033-1038.
71. Antequera F, Bird A. CpG islands [review]. EXS 1993, 64: 169-185.
72. Issa JP, Ottaviano YL, Celano P et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in the human colon. Nat Genet 1994, 7: 536-540.
73. Issa JP. CpG-island methylation in ageing and cancer. Current Topics Microbiol lmmunol 2000, 249: 101-118.
74. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999, 96: 8681-8686.
75. Costello JF, Fruhwald MC, Smiraglia et al. Abberant CpG-island methylation has non-random and tumour specific patterns. Nat Genet 2000, 24: 101-102.
76. Baylin SB, Herman JG. Promoter hypermethylation-can this change alone ever designate true tumour suppresser gene function. JNCI 2001, 93: 664-665.
77. Jubb A, Bell SM, Quirke P. An epi-mutator phenotype in colorectal cancer. J Pathol 2001, 195: 111-134.
78. Baylin SB, Herman JG, Graff JR et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998, 72: 141-96.
79. Jubb AM, Bell SM, Quirke P. Cyclooxygenase-2 expression in sporadic colorectal cancer. Pathol Soc Great Britain 2001, July, abstract 15.
80. Sutherland F, Bell SM, Gray et al. Loss of MGMT expression occurs more frequently in flat adenomas than polypoid adenomas or hyperplastic polyps. Pathol Soc Great Britain 2001, July, abstract 118.
81. 6methylguanine DNA methyltransferase characterises a subset of colorectal cancer with low level DNA microsatellite instability. Cancer Res 2001, 61: 827-830.
82. Sheehan KM, Shehan N, O'Donohue DP et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999, 282: 1254-1257.
83. Lindblom A. Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr Opin Oncol 2001, 13: 63-9.
84. Kitahara O, Furukawa Y, Tanaka T et al. Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumour tissues and normal epithelia. Cancer Res 2001, 61: 3544-9.
85. Maughan NJ, Heinemeyer E, Wieand D et al. Gene expression profiling and cluster analysis of colorectal cancer utilising DNA microarrays. Pathol Soc Great Britain 2001, July, abstract 26.
86. Thebo JS, Senagore AJ, Reinhold DS, Stapleton SR. Molecular staging of colorectal cancer: K-ras mutation analysis of lymph node upstages Dukes' B patients. Dis Colon Rectum 2000, 43: 155-162.
87. Kopreski MS, Benko FA, Borys DJ, Khan A, Mcgarrity JJ, Gocke CD. Somatic mutation screening: identification of individuals harbouring K-ras mutations with the use of plasma DNA. JNCI 2000, 92(11): 918-923.
88. De Kok JB, van Solinge WW, Ruers TJM et al. Detection of tumour DNA in serum of colorectal patients. Scand J Clin Lab Invest 1997, 57: 601-604.
89. Hammel P, Boissier B, Chaumette M-Tet et al. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 1997, 40: 356-361.
90. Euchi S, Kohara N, Komuta K, Kanematsu T. Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. Cancer 1996, 77: 1707-1710.
91. Villa E, Dugani A, Rebecchi AM et al. Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in stool. Gastroenterology 1996, 110: 1346-1353.
92. Puig P, Urgell E, Capella G et al. Improved detection of K-ras codon 12 mutations in fecal exfoliated cells. Lab Invest 1999, 79: 617-618.
93. Ahlquist DA, Skoletsky JE, Boynton KA et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000, 119: 1219-1227.
94. Moch H, Kononen T, Kallioniemi OP et al. Tissue microarrays: what will they bring to molecular and anatomicpathology? Adv Anat Pathol 2001, 8: 14-20.
95. Jass JR, Mukawa K, Goh HS et al. Clinical importance of DNA content in rectal cancer measured by flow cytometry. J Clin Pathol 1989, 42: 254-259.
96. Barratt PL, Seymour MT, Stenning S, Birbeck KF, Quirke P, and the AXIS collaborators. Molecular markers and the prediction of prognosis and response to therapy in colon cancer. J Pathol 1999, 189 (Suppl): 1A-28A.
97. Andreyev HJ, Normal AR, Cunningham D et al. Kirtsen ras mutations in patients with colorectal cancer: the multicentre 'RASCAL' study. JNCI 1998, 90: 675-685.
98. Kahlenberg MS, Stoler DL, Rodriguez-Bigas MA et al. P53 tumour suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma. Cancer 2000, 88: 1814-1819.
99. Hamelin R, Laurent-Puig P, Olschwang S, Jego W, Asselain B, Remvikos, Girodet J, Salmon R, Thomas G. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994, 106: 42-48.
100. Rodrigues NR, Rowan A, Smith MEF et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990, 87: 7555-7559.
101. Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B. Increased p53 protein concentration of colorectal tumours correlates with poor survival. Br J Cancer 1992, 66: 758-764.
102. Bosari S, Viale G, Bossi P, Maggioni M, Coggi G, Murray JJ et al. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. JNCI 1994, 86: 691-687.
103. Jen J, Kim H, Piantadosi S et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994, 331: 213-221.
104. Martinez-Lopez E, Abad A, Font A et al. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 1998, 114: 1180-1187.
105. Shibata D, Reale MA, Lavine P et al. Allelic loss on chromosome 18q as a prognostic marker in stage III colorectal cancer. Gastroenterology 1998, 114: 1180-1187.
106. Kern SE, Fearon ER, Tersmette. Clinical and pathological associations with allelic loss in colorecatl carcinoma. JAMA 1989, 261(21): 3099-3103.
107. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000, 355: 1745-1750.
108. Nicum S, Midgley R, Kerr DJ. Chemotherapy for colorectal cancer. J R Soc Med 2000, 93: 416-419.
109. IMPACT (international multicentre pooled analysis of colon cancer trials) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995, 345: 939-944.
110. Edler D, Hallstrom M, Johnston PG et al. Thymidylate synthase expression: an independent prognostic factor for local recurrence, a distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 2000, 6: 1378-1384.
111. Lander RD, Lynch FJ, Groshen S, Xiong YP, Sherrod A, Caradonna SJ, Stoehlmacher J, Lenz HJ. DUTP nucleotidohydrolase isoform expression in normal and neoplastic tissue: association with survival and response to 5-Fluorouracil in colorectal cancer. Cancer Res 2000, 60: 3493-3503.
112. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E, Illarramendi JJ, Arias F, Monge RF, Salgado E, Angeletti S, Brugarolas A. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict down-staging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001, 19: 1779-1786.
113. Horie N, Aiba H, Oguro K et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995, 20: 191-197.
114. Vermorken JB. Adjuvant immunotherapy in colorectal cancer. Semin Oncol 2000, 27 (5 Suppl 10): 66-71.
115. Hoover HC Jr, Brandhorst JS, Peters LC. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993, 11: 390-399.
116. Cobleigh MA, Vogel CL, Tripathy NJ et al. Efficacy and safety of Herceptin as a single agent in 222 women with Her2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1998, 17: 97a.
117. Slamon D, Leyland-Jones B, Shak et al. Addition of herceptin to first line chemotherapy for Her2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomised, multinational controlled phase III trial. Proc Soc Clin Oncol 1998, 17: 98a.
118. Utvinov SV, Velders MP, Bakker HAM, Fleuren GJ, Warnaar SO. Epcam: A human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125, 2: 437-446.
119. Adkins JC, Spencer CM. Edrecolomab. Drugs 1998, 56: 919-626.
120. Riethmuller G, Schneider-Gadicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma cancer. German cancer Aid 17-1A study group. Lancet 1994, 343: 1177-1183.
121. Riethmuller G, Schlimok G, Lehhmann JM et al. Immunological analysis of micro-metastases and the metastatic phenotype of human tumours. In: Melcher SF et al. (Eds.), Progress in Immunology vol. VII. Springer-Verlag, Berlin, 1989, pp. 1079-1086.
122. Huber BE, Austin EA, Good SS et al. In vivo anti-tumour activity of 5-fluorouracil on human CRC cells genetically modified to express cytosine deaminase. Cancer Res 1993, 53: 4619-4626.
123. Bookstein R, Demers W, Gregory R et al. P53 gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer. Semin Oncol 1996, 23: 66-77.